A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] in Hepatitis B, Chronic, sponsored by Hoffmann-La Roche. Completed at 31 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-09.
Sponsored by Hoffmann-La Roche · Phase 4 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic — 1 open to participants now, 1 under way, none of them phase 3. peginterferon alfa-2a · Hepatitis B, Chronic.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, this one is the 4th largest by enrollment, is one of 6 that started in 2009, is one of 29 in phase 4, and was the 15th registered.
896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.
Browse Hepatitis B, Chronic studies →1 of the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic is open now, in 4 countries. Recruiting first, the newest first:
IntegerBio · Sites in Hong Kong, Moldova, New Zealand and 1 more country
Ages 18–70 · Healthy volunteers
By country, each count listing its studies:
peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 12 · Phase 4 29
First in 2002; this study’s year is marked. 6 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 383 is above the median of 100 across 659 interventional studies indexed under Hepatitis B, Chronic.
Median enrollment 114 across the 59 interventional studies. Of the 39 that completed or were terminated, 17 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 59 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
46 studies in Hepatitis B, Chronic by Hoffmann-La Roche: none open now, none under way, none of them phase 3. Of 45 finished, 25 (56%) have results posted.
Among the 46 studies in Hepatitis B, Chronic by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 34 interventional ones that give a count, is one of 6 that started in 2009, is one of 16 in phase 4, and was the 9th registered.
Hoffmann-La Roche’s Hepatitis B, Chronic studies by the year they started, since 2002.
1 of the studies testing peginterferon alfa-2a in Hepatitis B, Chronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07389044IntegerBioA Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 59 studies testing peginterferon alfa-2a in Hepatitis B, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 46 in Hepatitis B, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is a long-term post-treatment follow-up to study WV19432, which evaluated the efficacy and safety of PEGASYS in patients with HBeAg positive chronic hepatitis B (CHB).Patients who received treatment with PEGASYS, and completed follow-up, are eligible to enter this post-treatment follow-up study. The anticipated time on study was 5 years, and the target sample size is 100-500 individuals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Pegasys (Pegylated interferon alfa-2a \[PEG-IFN\]) 90 micrograms (mcg) subcutaneously (SC) once a week for 24 weeks in Study WV19432 and entered follow-up (FU) Study MV22430.
Drug: peginterferon alfa-2a [Pegasys]
Participants received PEG-IFN 180 mcg SC once a week for 24 weeks in Study WV19432 and entered FU Study MV22430.
Drug: peginterferon alfa-2a [Pegasys]
Participants received PEG-IFN 90 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
Drug: peginterferon alfa-2a [Pegasys]
Participants received PEG-IFN 180 mcg SC once a week for 48 weeks in Study WV19432 and entered FU Study MV22430.
Drug: peginterferon alfa-2a [Pegasys]
90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
Percentage of Participants With Hepatitis B Envelope Antigen (HBeAg) Seroconversion.
HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe). Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With HBsAg Loss
HBsAg loss is defined as the absence of HBsAg (i.e. a negative result for HBsAg). Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With HBeAg Loss.
HBeAg loss is defined as the absence of HBeAg (i.e. a negative result for HBeAg). Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Hepatitis B Surface Antigen (HBsAg) Seroconversion.
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Presence of Anti-Hepatitis B Envelope Antigen (HBe).
The presence of anti-HBe is defined as antibody produced against e antigen in HBeAg. Seroconversion from e antigen to e antibody (anti-HBe) is a predictor of long-term clearance of hepatitis B virus (HBV) in participants undergoing antiviral therapy and indicates lower levels of HBV, and therefore lower infectivity. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Presence of Anti-HBs
The presence of anti-HBs is defined as antibody produced against HBsAg.It is generally interpreted as indicating recovery and immunity from HBV infection. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Normalised Alanine Transaminase (ALT)
Alanine Transaminase is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT levels increase. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 20,000 International Unit/Milliliter (IU/mL).
The percentage of participants with HBV-DNA suppression \< 20,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 2,000 International Unit/Milliliter (IU/mL)
The percentage of participants with HBV-DNA suppression \< 2,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Percentage of Participants With Hepatitis B Virus Deoxyribonucleic Acid (HBV-DNA) Suppression < 80 International Unit/Milliliter (IU/mL)
The percentage of participants with HBV-DNA suppression \< 80 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Quantitative HBsAg
Quantitative HBsAg assay is a diagnostic test for assessing the amount of the HBsAg in chronic Hepatitis B participants. Missing values were counted as non-response.
Time frame: Annually, for up to 5 years
Number of Participants Who Received Treatment With Antiviral, Immunomodulatory, Anti-inflammatory or Herbal/Botanical/Other Treatments for Chronic Hepatitis B
Participants who required additional treatments specifically to treat CHB, associated laboratory test abnormalities and associated symptoms in this long-term observation in the study were reported. Receipt of such treatment did not require participant withdrawal from further participation.
Time frame: Up to 5-year FU period
Number of Participants With Clinically Significant Events Related to Chronic Hepatitis B (CHB)
Clinically significant events were defined as one or more of the following: Hepatocellular carcinoma, hepatic decompensation, CHB-related death, hepatic transplant, marked elevation of serum ALT of \>10 x upper limit of normal (ULN).
Time frame: Up to 5-year FU period
Number of Participants With Marked Laboratory Abnormalities
Marked abnormality of laboratory parameters is defined as the value which is outside the defined reference range of that respective parameter. Roche's following reference ranges for laboratory test parameters were used for the analysis: Hemoglobin (reference range: 110-200 grams/liter\[g/L\]), White blood cells (WBC) (3.0-18.0 \^10\^9/L), Platelets (100-550 \^10\^9/L), Neutrophils (1.50-9.25 \^10\^9/L), Prothrombin time (PT) Normal ratio (n.d.-2.00), Alkaline phosphatase (0-220 units/liter \[U/L\]), Alanine aminotransferase (0-110 U/L), Aspartate transaminase (0-80 U/L), Total bilirubin (0-34 micromole/liter \[umol/L\]), Gamma-glutamyl transpeptidase (GGT) (0-190 U/L), Blood urea nitrogen (BUN) (0.0-14.3 millimole/liter \[mmol/L\]), Creatinine (0-154 umol/L), Total Protein (55-87 g/L), Albumin (30.0-n.d. g/L), Potassium (2.9-5.8 mmol/L), Sodium (130-150 mmol/L), Calcium (2.00-2.90 mmol/L), Uric acid (0-600 umol/L). It includes marked abnormalities observed during Study WV19432 and FU study MV22430
Time frame: Up to 5-year FU period
The study was conducted from 10 April 2009 to 05 November 2014. A total of 383 participants were recruited from 31 centers across 9 countries (Australia, New Zealand, China, Taiwan, Singapore, Korea, Thailand, Brazil, and Russia).
| Milestone | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| Started | 91 | 87 | 108 | 97 |
| Completed | 79 | 77 | 86 | 78 |
| Not completed | 12 | 10 | 22 | 19 |
| Withdrew: Lost to follow-up | 9 | 8 | 12 | 16 |
| Withdrew: Withdrawal by subject | 3 | 2 | 7 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Screen fail,participant migrated,unknown | 0 | 0 | 2 | 1 |
HBeAg seroconversion was defined as the absence of HBeAg (a negative result for HBeAg) and the presence of anti-HBe (a positive result for anti-HBe). Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| End of Treatment (EOT) | 9.7 (4.5 to 17.6) | 14.6 (8.0 to 23.7) | 19.8 (12.7 to 28.7) | 31.6 (22.4 to 41.9) |
| FU Year 1 | 20.4 (12.8 to 30.1) | 31.5 (22.0 to 42.2) | 27.4 (19.1 to 36.9) | 35.8 (26.2 to 46.3) |
| FU Year 2 | 26.9 (18.2 to 37.1) | 37.1 (27.1 to 48.0) | 30.2 (21.7 to 39.9) | 47.4 (37.0 to 57.9) |
| FU Year 3 | 38.7 (28.8 to 49.4) | 40.4 (30.2 to 51.4) | 34.0 (25.0 to 43.8) | 52.6 (42.1 to 63.0) |
| FU Year 4 | 37.6 (27.8 to 48.3) | 44.9 (34.4 to 55.9) | 41.5 (32.0 to 51.5) | 49.5 (39.1 to 59.9) |
| FU Year 5 | 41.9 (31.8 to 52.6) | 44.9 (34.4 to 55.9) | 40.6 (31.1 to 50.5) | 48.4 (38.0 to 58.9) |
HBeAg loss is defined as the absence of HBeAg (i.e. a negative result for HBeAg). Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 9.7 (4.5 to 17.6) | 14.6 (8.0 to 23.7) | 19.8 (12.7 to 28.7) | 33.7 (24.3 to 44.1) |
| FU Year 1 | 23.7 (15.5 to 33.6) | 31.5 (22.0 to 42.2) | 30.2 (21.7 to 39.9) | 36.8 (27.2 to 47.4) |
| FU Year 2 | 30.1 (21.0 to 40.5) | 38.2 (28.1 to 49.1) | 33.0 (24.2 to 42.8) | 48.4 (38.0 to 58.9) |
| FU Year 3 | 41.9 (31.8 to 52.6) | 46.1 (35.4 to 57.0) | 38.7 (29.4 to 48.6) | 53.7 (43.2 to 64.0) |
| FU Year 4 | 46.2 (35.8 to 56.9) | 49.4 (38.7 to 60.2) | 49.1 (39.2 to 59.0) | 53.7 (43.2 to 64.0) |
| FU Year 5 | 50.5 (40.0 to 61.1) | 49.4 (38.7 to 60.2) | 50.0 (40.1 to 59.9) | 51.6 (41.1 to 62.0) |
HBsAg seroconversion was defined as the absence of HBsAg (a negative result for HBsAg) and the presence of anti-HBs (a positive result for anti-HBs). Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 0.0 (0.0 to 3.9) | 1.1 (0.0 to 6.1) | 1.9 (0.2 to 6.6) | 3.2 (0.7 to 9.0) |
| FU Year 1 | 1.1 (0.0 to 5.8) | 0.0 (0.0 to 4.1) | 0.9 (0.0 to 5.1) | 1.1 (0.0 to 5.7) |
| FU Year 2 | 2.2 (0.3 to 7.6) | 0.0 (0.0 to 4.1) | 0.9 (0.0 to 5.1) | 3.2 (0.7 to 9.0) |
| FU Year 3 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 0.9 (0.0 to 5.1) | 3.2 (0.7 to 9.0) |
| FU Year 4 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 0.9 (0.0 to 5.1) | 2.1 (0.3 to 7.4) |
| FU Year 5 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 1.9 (0.2 to 6.6) | 2.1 (0.3 to 7.4) |
The presence of anti-HBe is defined as antibody produced against e antigen in HBeAg. Seroconversion from e antigen to e antibody (anti-HBe) is a predictor of long-term clearance of hepatitis B virus (HBV) in participants undergoing antiviral therapy and indicates lower levels of HBV, and therefore lower infectivity. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 23.7 (15.5 to 33.6) | 27.0 (18.1 to 37.4) | 29.2 (20.8 to 38.9) | 40.0 (30.1 to 50.6) |
| FU Year 1 | 28.0 (19.1 to 38.2) | 42.7 (32.3 to 53.6) | 28.3 (20.0 to 37.9) | 38.9 (29.1 to 49.5) |
| FU Year 2 | 31.2 (22.0 to 41.6) | 40.4 (30.2 to 51.4) | 33.0 (24.2 to 42.8) | 50.5 (40.1 to 60.9) |
| FU Year 3 | 41.9 (31.8 to 52.6) | 42.7 (32.3 to 53.6) | 36.8 (27.6 to 46.7) | 55.8 (45.2 to 66.0) |
| FU Year 4 | 37.6 (27.8 to 48.3) | 44.9 (34.4 to 55.9) | 41.5 (32.0 to 51.5) | 52.6 (42.1 to 63.0) |
| FU Year 5 | 43.0 (32.8 to 53.7) | 48.3 (37.6 to 59.2) | 42.5 (32.9 to 52.4) | 50.5 (40.1 to 60.9) |
The presence of anti-HBs is defined as antibody produced against HBsAg.It is generally interpreted as indicating recovery and immunity from HBV infection. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 4.3 (1.2 to 10.6) | 2.2 (0.3 to 7.9) | 11.3 (6.0 to 18.9) | 9.5 (4.4 to 17.2) |
| FU Year 1 | 6.5 (2.4 to 13.5) | 3.4 (0.7 to 9.5) | 7.5 (3.3 to 14.3) | 7.4 (3.0 to 14.6) |
| FU Year 2 | 5.4 (1.8 to 12.1) | 10.1 (4.7 to 18.3) | 6.6 (2.7 to 13.1) | 6.3 (2.4 to 13.2) |
| FU Year 3 | 4.3 (1.2 to 10.6) | 4.5 (1.2 to 11.1) | 7.5 (3.3 to 14.3) | 5.3 (1.7 to 11.9) |
| FU Year 4 | 4.3 (1.2 to 10.6) | 3.4 (0.7 to 9.5) | 4.7 (1.5 to 10.7) | 5.3 (1.7 to 11.9) |
| FU Year 5 | 3.2 (0.7 to 9.1) | 4.5 (1.2 to 11.1) | 5.7 (2.1 to 11.9) | 5.3 (1.7 to 11.9) |
Alanine Transaminase is an enzyme found mainly in liver and is measured to check if the liver is damaged or diseased. In case of liver damage or disease, the liver releases ALT into the blood stream and the ALT levels increase. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 28.0 (19.1 to 38.2) | 27.0 (18.1 to 37.4) | 38.7 (29.4 to 48.6) | 49.5 (39.1 to 59.9) |
| FU Year 1 | 45.2 (34.8 to 55.8) | 44.9 (34.4 to 55.9) | 49.1 (39.2 to 59.0) | 50.5 (40.1 to 60.9) |
| FU Year 2 | 58.1 (47.4 to 68.2) | 60.7 (49.7 to 70.9) | 55.7 (45.7 to 65.3) | 65.3 (54.8 to 74.7) |
| FU Year 3 | 66.7 (56.1 to 76.1) | 70.8 (60.2 to 79.9) | 54.7 (44.8 to 64.4) | 66.3 (55.9 to 75.7) |
| FU Year 4 | 67.7 (57.3 to 77.1) | 64.0 (53.2 to 73.9) | 62.3 (52.3 to 71.5) | 63.2 (52.6 to 72.8) |
| FU Year 5 | 69.9 (59.5 to 79.0) | 67.4 (56.7 to 77.0) | 56.6 (46.6 to 66.2) | 63.2 (52.6 to 72.8) |
HBsAg loss is defined as the absence of HBsAg (i.e. a negative result for HBsAg). Missing values were counted as non-response.
| Percentage | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 0.0 (0.0 to 3.9) | 1.1 (0.0 to 6.1) | 1.9 (0.2 to 6.6) | 3.2 (0.7 to 9.0) |
| FU Year 1 | 1.1 (0.0 to 5.8) | 0.0 (0.0 to 4.1) | 0.9 (0.0 to 5.1) | 1.1 (0.0 to 5.7) |
| FU Year 2 | 2.2 (0.3 to 7.6) | 0.0 (0.0 to 4.1) | 1.9 (0.2 to 6.6) | 3.2 (0.7 to 9.0) |
| FU Year 3 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 1.9 (0.2 to 6.6) | 3.2 (0.7 to 9.0) |
| FU Year 4 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 2.8 (0.6 to 8.0) | 2.1 (0.3 to 7.4) |
| FU Year 5 | 3.2 (0.7 to 9.1) | 0.0 (0.0 to 4.1) | 2.8 (0.6 to 8.0) | 2.1 (0.3 to 7.4) |
The percentage of participants with HBV-DNA suppression \< 20,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 22.6 (14.6 to 32.4) | 33.7 (24.0 to 44.5) | 34.0 (25.0 to 43.8) | 50.5 (40.1 to 60.9) |
| FU Year 1 | 33.3 (23.9 to 43.9) | 31.5 (22.0 to 42.2) | 45.3 (35.6 to 55.2) | 40.0 (30.1 to 50.6) |
| FU Year 2 | 57.0 (46.3 to 67.2) | 50.6 (39.8 to 61.3) | 58.5 (48.5 to 68.0) | 54.7 (44.2 to 65.0) |
| FU Year 3 | 67.7 (57.3 to 77.1) | 61.8 (50.9 to 71.9) | 61.3 (51.4 to 70.6) | 64.2 (53.7 to 73.8) |
| FU Year 4 | 69.9 (59.5 to 79.0) | 68.5 (57.8 to 78.0) | 68.9 (59.1 to 77.5) | 64.2 (53.7 to 73.8) |
| FU Year 5 | 67.7 (57.3 to 77.1) | 70.8 (60.2 to 79.9) | 67.0 (57.2 to 75.8) | 63.2 (52.6 to 72.8) |
The percentage of participants with HBV-DNA suppression \< 2,000 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 15.1 (8.5 to 24.0) | 21.3 (13.4 to 31.3) | 27.4 (19.1 to 36.9) | 45.3 (35.0 to 55.8) |
| FU Year 1 | 20.4 (12.8 to 30.1) | 23.6 (15.2 to 33.8) | 39.6 (30.3 to 49.6) | 31.6 (22.4 to 41.9) |
| FU Year 2 | 45.2 (34.8 to 55.8) | 39.3 (29.1 to 50.3) | 50.0 (40.1 to 59.9) | 45.3 (35.0 to 55.8) |
| FU Year 3 | 52.7 (42.1 to 63.1) | 52.8 (41.9 to 63.5) | 52.8 (42.9 to 62.6) | 52.6 (42.1 to 63.0) |
| FU Year 4 | 59.1 (48.5 to 69.2) | 56.2 (45.3 to 66.7) | 63.2 (53.3 to 72.4) | 54.7 (44.2 to 65.0) |
| FU Year 5 | 59.1 (48.5 to 69.2) | 61.8 (50.9 to 71.9) | 60.4 (50.4 to 69.7) | 57.9 (47.3 to 68.0) |
The percentage of participants with HBV-DNA suppression \< 80 IU/mL. HBV DNA is the genetic material that carries the blueprint of the virus. The measure of HBV DNA in blood indicates how rapidly the virus is replicating in liver. Missing values were counted as non-response.
| Percentage of participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT | 5.4 (1.8 to 12.1) | 12.4 (6.3 to 21.0) | 16.0 (9.6 to 24.4) | 32.6 (23.4 to 43.0) |
| FU Year 1 | 12.9 (6.8 to 21.5) | 7.9 (3.2 to 15.5) | 17.9 (11.2 to 26.6) | 14.7 (8.3 to 23.5) |
| FU Year 2 | 28.0 (19.1 to 38.2) | 23.6 (15.2 to 33.8) | 36.8 (27.6 to 46.7) | 29.5 (20.6 to 39.7) |
| FU Year 3 | 39.8 (29.8 to 50.5) | 30.3 (21.0 to 41.0) | 34.9 (25.9 to 44.8) | 38.9 (29.1 to 49.5) |
| FU Year 4 | 47.3 (36.9 to 57.9) | 38.2 (28.1 to 49.1) | 46.2 (36.5 to 56.2) | 40.0 (30.1 to 50.6) |
| FU Year 5 | 39.8 (29.8 to 50.5) | 40.4 (30.2 to 51.4) | 42.5 (32.9 to 52.4) | 38.9 (29.1 to 49.5) |
Quantitative HBsAg assay is a diagnostic test for assessing the amount of the HBsAg in chronic Hepatitis B participants. Missing values were counted as non-response.
| log10 IU/mL | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| EOT (n= 89, 86, 102, 91) | 3.541 ± 0.9523 | 3.371 ± 1.1570 | 3.322 ± 1.0875 | 2.949 ± 1.3170 |
| FU Year 1 (n= 87, 85, 93, 86) | 3.495 ± 0.9314 | 3.484 ± 0.8102 | 3.379 ± 0.9076 | 3.453 ± 0.9282 |
| FU Year 2 (n= 86, 86, 96, 90) | 3.478 ± 0.9263 | 3.441 ± 0.7682 | 3.381 ± 0.8898 | 3.318 ± 1.0139 |
| FU Year 3 (n= 83, 82, 91, 85) | 3.479 ± 0.9008 | 3.393 ± 0.7095 | 3.339 ± 0.8870 | 3.178 ± 1.0561 |
| FU Year 4 (n= 81, 79, 89, 80) | 3.456 ± 0.9418 | 3.350 ± 0.8172 | 3.240 ± 0.9143 | 3.135 ± 0.9906 |
| FU Year 5 (n= 81, 79, 83, 74) | 3.391 ± 0.8555 | 3.305 ± 0.8206 | 3.201 ± 0.9099 | 2.932 ± 1.1391 |
Participants who required additional treatments specifically to treat CHB, associated laboratory test abnormalities and associated symptoms in this long-term observation in the study were reported. Receipt of such treatment did not require participant withdrawal from further participation.
| Participants | Group A | Group B | Group C | Group D |
|---|---|---|---|---|
| Nucleoside/nucleotide analogues | 49 | 40 | 51 | 36 |
| Antiviral agents | 9 | 7 | 18 | 9 |
| Cytokines | 2 | 8 | 9 | 9 |
| Botanicals | 4 | 6 | 4 | 9 |
| Miscellaneous gastrointestinal agents | 5 | 3 | 4 | 7 |
| Miscellaneous drugs | 1 | 1 | 2 | 1 |
| Supplements | 2 | 1 | 1 | 0 |
| Pharmaceutic aids | 1 | 1 | 1 | 0 |
| Immunomodulators | 0 | 2 | 0 | 0 |
| Blood products | 0 | 1 | 0 | 0 |
| Chelating agents | 0 | 1 | 0 | 0 |
| Clotting factors and haemostatics | 0 | 1 | 0 | 0 |
| Prostaglandins | 0 | 1 | 0 | 0 |
| Vaccines, toxoids and serologic agents | 0 | 1 | 0 | 0 |
| Vitamins and minerals | 1 | 0 | 0 | 0 |
Clinically significant events were defined as one or more of the following: Hepatocellular carcinoma, hepatic decompensation, CHB-related death, hepatic transplant, marked elevation of serum ALT of \>10 x upper limit of normal (ULN).
| Participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| Elevated ALT >10 x ULN (Yes) | 3 | 5 | 9 | 5 |
| Elevated ALT >10 x ULN (No) | 89 | 83 | 97 | 90 |
| Elevated ALT >10 x ULN (Missing) | 1 | 1 | 0 | 0 |
| Hepatic Decompensation (Yes) | 2 | 0 | 1 | 1 |
| Hepatic Decompensation (No) | 88 | 87 | 105 | 94 |
| Hepatic Decompensation (Missing) | 3 | 2 | 0 | 0 |
| Hepatocellular Carcinoma (Yes) | 1 | 0 | 3 | 0 |
| Hepatocellular Carcinoma (No) | 20 | 22 | 22 | 21 |
| Hepatocellular Carcinoma (No assessment performed) | 71 | 66 | 81 | 74 |
| Hepatocellular Carcinoma (Missing) | 1 | 1 | 0 | 0 |
| Hepatic Transplant (No) | 92 | 88 | 106 | 95 |
| Hepatic Transplant (Missing) | 1 | 1 | 0 | 0 |
Marked abnormality of laboratory parameters is defined as the value which is outside the defined reference range of that respective parameter. Roche's following reference ranges for laboratory test parameters were used for the analysis: Hemoglobin (reference range: 110-200 grams/liter\[g/L\]), White blood cells (WBC) (3.0-18.0 \^10\^9/L), Platelets (100-550 \^10\^9/L), Neutrophils (1.50-9.25 \^10\^9/L), Prothrombin time (PT) Normal ratio (n.d.-2.00), Alkaline phosphatase (0-220 units/liter \[U/L\]), Alanine aminotransferase (0-110 U/L), Aspartate transaminase (0-80 U/L), Total bilirubin (0-34 micromole/liter \[umol/L\]), Gamma-glutamyl transpeptidase (GGT) (0-190 U/L), Blood urea nitrogen (BUN) (0.0-14.3 millimole/liter \[mmol/L\]), Creatinine (0-154 umol/L), Total Protein (55-87 g/L), Albumin (30.0-n.d. g/L), Potassium (2.9-5.8 mmol/L), Sodium (130-150 mmol/L), Calcium (2.00-2.90 mmol/L), Uric acid (0-600 umol/L). It includes marked abnormalities observed during Study WV19432 and FU study MV22430
| Participants | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| Alanine transaminase (High) | 66 | 67 | 74 | 56 |
| Aspartate transaminase (High) | 60 | 60 | 60 | 51 |
| Albumin (Low) | 1 | 2 | 1 | 0 |
| Alkaline phosphatase (High) | 0 | 2 | 1 | 1 |
| BUN (High) | 0 | 0 | 1 | 0 |
| Calcium (High) | 0 | 0 | 1 | 2 |
| Calcium (Low) | 5 | 5 | 15 | 7 |
| Creatinine (High) | 0 | 0 | 1 | 0 |
| GGT (High) | 3 | 5 | 7 | 7 |
| Hemoglobin (Low) | 5 | 6 | 1 | 13 |
| Neutrophils (High) | 3 | 2 | 2 | 2 |
| Neutrophils (Low) | 53 | 57 | 79 | 77 |
| PT normalized ratio (High) | 0 | 1 | 0 | 0 |
| Platelets (Low) | 14 | 23 | 28 | 41 |
| Potassium (High) | 2 | 1 | 4 | 2 |
| Potassium (Low) | 1 | 0 | 0 | 1 |
| Prothrombin time (High) | 0 | 1 | 1 | 0 |
| Sodium (High) | 3 | 0 | 1 | 0 |
| Sodium (Low) | 0 | 0 | 1 | 0 |
| Total bilirubin (High) | 2 | 4 | 8 | 3 |
| Total protein (High) | 3 | 1 | 5 | 6 |
| Total Protein (Low) | 1 | 0 | 1 | 0 |
| Uric acid (High) | 1 | 1 | 2 | 1 |
| White blood cell (Low) | 27 | 34 | 52 | 65 |
Collected over 5-year FU period. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN 90mcg 24 Wks | — | 5/93 (5.4%) | 8/93 (8.6%) |
| PEG-IFN 180mcg 24 Wks | — | 4/89 (4.5%) | 8/89 (9%) |
| PEG-IFN 90mcg 48 Wks | — | 10/106 (9.4%) | 8/106 (7.5%) |
| PEG-IFN 180mcg 48 Wks | — | 6/95 (6.3%) | 12/95 (12.6%) |
| Event | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/93 | 0/89 | 3/106 | 0/95 |
| Hepatic function abnormalHepatobiliary disorders | 0/93 | 1/89 | 0/106 | 0/95 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/93 | 1/89 | 1/106 | 0/95 |
| Pancreatitis acuteGastrointestinal disorders | 1/93 | 1/89 | 0/106 | 0/95 |
| Ovarian cystReproductive system and breast disorders | 0/93 | 1/89 | 0/106 | 0/95 |
| Dengue feverInfections and infestations | 1/93 | 0/89 | 0/106 | 0/95 |
| Hepatitis BInfections and infestations | 1/93 | 0/89 | 0/106 | 0/95 |
| Ectopic pregnancyPregnancy, puerperium and perinatal conditions | 1/93 | 0/89 | 0/106 | 0/95 |
| Alanine aminotransferase increasedInvestigations | 1/93 | 0/89 | 0/106 | 1/95 |
| Gastrointestinal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/93 | 0/89 | 0/106 | 1/95 |
| Event | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 5/93 | 6/89 | 4/106 | 7/95 |
| Alanine aminotransferase increasedInvestigations | 3/93 | 2/89 | 4/106 | 5/95 |
The Intent-to-Treat analysis population included all participants who had received at least one dose of study medication in study WV19432 and provided informed consent for study MV22430. Participants were analyzed according to the treatment groups to which they had been randomized.
| Age, Continuous(years) | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks | Total |
|---|---|---|---|---|---|
| Mean | 32.5 ± 9.73 | 34.5 ± 10.54 | 34.3 ± 10.82 | 34.2 ± 10.78 | 33.9 ± 10.49 |
| Sex: Female, Male(Participants) | PEG-IFN 90mcg 24 Wks | PEG-IFN 180mcg 24 Wks | PEG-IFN 90mcg 48 Wks | PEG-IFN 180mcg 48 Wks | Total |
|---|---|---|---|---|---|
| Female | 34 | 23 | 33 | 35 | 125 |
| Male | 57 | 64 | 75 | 62 | 258 |
The record gives a start of Apr 2009, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Peginterferon alfa-2a